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Abstract We evaluated the associations between glycemic therapies and prevalence
of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and
revascularization therapies for coronary artery disease (CAD) and on insulin-sensitizing vs.
insulin-providing treatments for diabetes. A total of 2,368 patients with type 2 diabetes
and CAD was evaluated. DPN was defined as clinical examination score .2 using the
Michigan Neuropathy Screening Instrument (MNSI). DPN odds ratios across different
groups of glycemic therapy were evaluated by multiple logistic regression adjusted for
multiple covariates including age, sex, hemoglobin A1c (HbA1c), and diabetes duration.
Fifty-one percent of BARI 2D subjects with valid baseline characteristics and MNSI scores
had DPN. After adjusting for all variables, use of insulin was significantly associated with
DPN (OR ¼ 1.57, 95% CI: 1.15–2.13). Patients on sulfonylurea (SU) or combination of SU/
metformin (Met)/thiazolidinediones (TZD) had marginally higher rates of DPN than the
Met/TZD group. This cross-sectional study in a cohort of patients with type 2 diabetes
and CAD showed association of insulin use with higher DPN prevalence, independent of
disease duration, glycemic control, and other characteristics. The causality between a gly-
cemic control strategy and DPN cannot be evaluated in this cross-sectional study, but
continued assessment of DPN and randomized therapies in BARI 2D trial may provide
further explanations on the development of DPN.
Key words: coronary artery disease, diabetic peripheral neuropathy, glycemic control
therapy, Michigan Neuropathy Screening Instrument, type 2 diabetes
Introduction
In the United States, more than 23 million people
aged 20 years and older have diabetes (http://
www.diabetes.org and http://www.cdc.gov), and the
incidence is increasing by 5% per year. Diabetic
peripheral neuropathy (DPN) is the most common
chronic complication of diabetes and is the leading
cause of diabetes-related hospital admissions
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and non-traumatic amputations (Pirart, 1977; Boulton
et al., 2005). DPN leads to major physical disability,
poor quality of life (Vileikyte et al., 2005), high mortality
(Boulton et al., 2005), and estimated total annual costs
of $22 billion (http://www.diabetes.org and http://www.
cdc.gov). Despite its high morbidity (Boulton et al.,
2005), results from most randomized clinical trials as-
sessing the efficacy of various therapeutic agents have
been disappointing, most likely due to the complexity of
mechanisms involved in its pathogenesis (Pop-Busui
et al., 2006). Therefore, to date, no effective treatment
exists for DPN other than control of hyperglycemia
(DCCT Research Group, 1995; Ohkubo et al., 1995).
The initial screening and diagnosis of DPN in clinical
practice depend on assessment of subjective com-
plaints. A variety of validated scales and composite
scores semiquantitatively assess sensation, strength,
and reflexes and are frequently used as the primary out-
come measure in clinical trials (Dyck et al., 1997; Dyck,
2003). The Michigan Neuropathy Screening Instrument
(MNSI) is a validated clinical screening instrument for
the assessment of DPN designed to balance the contri-
bution of motor and sensory findings (Feldman et al.,
1994) and has been widely used in clinical trials and lon-
gitudinal cohort studies including the Diabetes Control
and Complications Trial/Epidemiology of Diabetes Inten-
sive Control study (Brown et al., 2004; Martin et al.,
2006). The examination score of the MNSI was estab-
lished to achieve high specificity (95%) and sensitivity
(80%), with a positive predictive value of 97% and a
negative predictive value of 74% (Feldman et al., 1994).
The Bypass Angioplasty Revascularization Investi-
gation 2 Diabetes (BARI 2D) trial is a National Institutes
of Health–sponsored randomized clinical trial that eval-
uates treatment efficacy for patients with type 2 diabe-
tes mellitus (T2DM) and angiographically documented,
stable coronary artery disease (CAD) (BARI 2D Study
Group, 2008). One of the unique hypotheses of the
BARI 2D trial is that insulin-providing agents will differ
from insulin-sensitizing agents in their effects on car-
diovascular outcomes (BARI 2D Study Group, 2008).
DPN as assessed by the MNSI at baseline and annual
examinations thereafter is one of the secondary out-
comes followed in the BARI 2D cohort.
Intensive glycemic control can reduce the inci-
dence of neuropathy in both type 1 and type 2 diabetic
subjects (DCCT Research Group, 1995; Ohkubo et al.,
1995), but different antidiabetic agents may have other
effects besides lowering glucose. For instance, animal
studies reported beneficial effects of the insulin sensi-
tizers (IS), TZD and metformin (Met), on markers of
experimental DPN via prevention of increased oxidative
stress, inflammation and signaling in the protein kinase
C pathway (Yamagishi et al., 2008), and prevention of
neuronal apoptosis (El-Mir et al., 2008). However,
whether different antidiabetic therapies could play
a role in DPN prevalence in T2DM or whether IS may
be protective is unknown. The association of diabetic
therapies and the prevalence of DPN have been
reported in population studies (Franklin et al., 1994;
Savage et al., 1997; el-Shazly et al., 1998), but those
findings from over 10 years ago would not reflect the
use of newer drugs such as Met and/or TZD for glyce-
mic control. Therefore, in this large, ethnically diverse
cohort of patients with type 2 diabetes in the BARI 2D
trial, we examined the association of prior diabetes
therapy and the prevalence of DPN at baseline.
Materials and Methods
The BARI 2D trial design and patient population
have been described elsewhere (BARI 2D Study
Group, 2008). Briefly, a total of 2,368 patients, with
T2DM and angiographically documented CAD, were
recruited from 49 international clinical sites and ran-
domized to early revascularization and aggressive
medical therapy vs. aggressive medical therapy alone
and to insulin-sensitizing vs. insulin-providing treat-
ments for diabetes. All participants signed an informed
consent, and the study was approved by institutional
review boards at all participating institutions.
Glycemia treatments
Upon enrollment, the current diabetes manage-
ment regimen was recorded (within 6 months), and
laboratory data were obtained on all participants (BARI
2D Study Group, 2008). The glycemic control medica-
tion for the present analysis was categorized into five
mutually exclusive classes: (1) no diabetes medica-
tion; (2) IS only, which included Met and/or TZD; (3)
insulin providers (IP) only without insulin, which
included sulfonylurea (SU) and/or meglitinide and/or
phenylalanine derivative (SU for all); (4) combination of
IS and IP without insulin (Met/TZD þ SU); and (5)
insulin alone or in combination with any other diabe-
tes medication(s) (insulin). The neutral agents, alpha
glucosidase inhibitors, were not categorized sepa-
rately from IS or IP drugs because only 26 patients
took these drugs at baseline, and they were equally
distributed among the five groups.
Neuropathy screening
The MNSI consists of a brief symptom question-
naire of 15 ‘yes or no’ questions on foot sensation
and a clinical examination (Feldman et al., 1994). The
clinical examination portion of the MNSI, the most
objective portion, is a simple 8-point score evaluating
ankle reflexes, light touch and vibration sensation in
the great toe, and foot appearance. One point per side
is assigned for abnormalities of foot appearance
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(deformities, dry skin, calluses, infection, and ulcers)
and 1 point per side (in 0.5 point increments) for abnor-
malities of ankle reflexes and light touch or vibration at
the great toe. BARI 2D nurse coordinators were trained
in a central session and certified to perform the MNSI
in all BARI 2D subjects at the enrollment visit. DPN
was defined operationally as a score greater than 2.0
on the MNSI examination, thresholds defined by prior
validation studies (Feldman et al., 1994; Brown et al.,
2004; Martin et al., 2006). A score .2 requires at least
one abnormality in reflexes, vibration, or light touch.
Statistical methods
The primary outcome was the presence of DPN
as defined by a MNSI clinical score .2. Relevant
baseline characteristics of demographics, lifestyle,
clinical history, and laboratory measures were evalu-
ated for the association with DPN, using chi-square
tests and Student’s t tests to test the significance at
an alpha level of 0.05. Logistic regression models
were built to evaluate the association of DPN with
glycemic control therapies. To test our hypothesis, pa-
tients on Met/TZD only were selected as the refer-
ence group. A model was built to estimate the
unadjusted odds ratios of DPN by glycemic control
medication, without any other covariates in the
model. The following covariates were then added to
the model: demographic characteristics (sex, age, and
race/ethnicity), current cigarette use and alcohol con-
sumption as categorical variables and hemoglobin A1c
(HbA1c), diabetes duration, body mass index, systolic
blood pressure, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, and triglycerides
as continuous variables. Although age and duration of
diabetes mellitus (DM) are statistically correlated,
they are not collinear and independently contribute to
the model. Significance was evaluated at a 0.05 level
for all odds ratio estimates. SAS v.9.1.3 software was
used for all data processing and statistical analysis.
Results
Among the 2,368 patients enrolled in the BARI 2D
trial, 2,314 patients had valid baseline MNSI clinical
scores, specified glycemic control strategies, and at
least 80% baseline information available. This group
formed the basis of the present analysis.
The demographic and clinical characteristics show
a cohort with an average age of 62.4  8.9 years,
with predominance of males (71%) and of non-
Hispanic whites (66%) (Table 1). Forty-three percent
of these subjects reported more than 10 years diabe-
tes duration (mean: 10.4  8.7 years) and 61% had an
HbA1c above target (i.e., 7%) at baseline (HbA1c
mean  SD: 7.7  1.6).
At baseline, the MNSI clinical score ranged from
0 to 8. Of the 2,314 subjects, 1,173 (51%) had a MNSI
clinical score .2 consistent with DPN (Fig. 1). In this
cohort, the higher prevalence of DPN was significantly
associated with older age, male sex, black non-Hispanic
ethnicity, longer diabetes duration, HbA1c  7%, his-
tory of hypertension and albuminuria (p , 0.05)
(Table 1). On the other hand, none of the lipid variables,
current cigarette use, or ethanol intake was significantly
associated with the prevalence of DPN (Table 1). Of
note, 79% of the subjects were on treatment for dysli-
pidemia. The mean diabetes duration and HbA1c corre-
lated with each other in the different glycemic control
therapy groups with the shortest duration and lowest
mean HbA1c values in subjects without a diabetes drug
and the longest duration and highest HbA1c values in
the subjects treated with insulin (Table 2).
In unadjusted analysis, subjects treated only with
Met/TZD had the lowest DPN prevalence compared
with the other groups and were therefore used as the
comparator group for further analysis. Subjects trea-
ted with insulin had the highest DPN prevalence at
baseline (Table 2, p , 0.001). After adjusting for all
the selected covariates including HbA1c and DM
duration, the use of insulin was associated with a sig-
nificant increase in the rate of DPN compared with
Met/TZD group (Fig. 2). Subjects in the SU or on the
SU-Met/TZD groups had insignificantly higher rate of
DPN than the Met/TZD group (Fig. 2).
To further investigate the association of insulin
use and the prevalence of DPN, we analyzed the rate
of DPN in all insulin users compared with all non-
insulin users at the time of randomization. In a logistic
regression model that simultaneously adjusted for all
the covariates mentioned in the methods, the ORs of
DPN remained more than 30% higher in subjects tak-
ing insulin compared with subjects not taking insulin
(OR ¼ 1.34, 95% CI: 1.08–1.67).
Given the importance of DM duration to the risk of
neuropathy, we analyzed the prevalence of DPN in
a subgroup of the cohort who reported a diabetes dura-
tion 10 years. Based on this subgroup analysis, insulin
use was associated with about a twofold higher preva-
lence of DPN compared with the Met/TZD group (OR ¼
1.91, 95% CI: 1.0–3.6). In this subgroup, insulin users
had also higher prevalence of DPN compared with all
non-insulin users (OR ¼ 1.32, 95% CI: 0.99–1.76).
Discussion
In this ethnically diverse and large cohort of pa-
tients with T2DM and angiographically confirmed CAD,
we observed a high prevalence of DPN (51%) using
a validated, easy-to-use clinical instrument. In addition,
after controlling for age, sex, race/ethnicity, diabetes
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duration, HbA1c, and all other described variables, insu-
lin use at baseline was the glycemic control strategy
that was independently associated with a significantly
higher prevalence of DPN. On the other hand, a lower
prevalence of DPN was seen in the Met/TZD group
compared with all other diabetes medication groups,
although it did not reach statistical significance.
In general, the development of diabetic complica-
tions is related to the degree of metabolic control that
is determined by multiple factors. Until recently,
hyperglycemia, the common clinical expression of
both types of diabetes, has been regarded as the
major culprit initiating the cascade of metabolic and
molecular abnormalities resulting in degenerative phe-
nomena and progressive neurological deficits. This
concept alone, however, does not account for the re-
sults from trials designed to achieve optimal glycemic
control but only show a partial reduction in the deve-
lopment of complications in general and on neuropa-
thy in particular (DCCT Research Group, 1995; 1998;
Azad et al., 1999). These data therefore suggest that
factors other than hyperglycemia are involved in the
pathophysiology of DPN and that such factors may
account for the differences in the prevalence and pro-
gression of DPN.
At study entry in BARI 2D, the use of insulin was
significantly associated with higher rates of DPN in
a cross-sectional analysis even after adjusting for
many identified confounders such as HbA1c and dura-
tion of diabetes. Some prior and smaller observational
studies reported similar associations. For instance,
a cross-sectional population study of 890 T2DM sub-
jects from the Denver metropolitan area reported
that the use of insulin was significantly associated
with the presence of all microangiopathic complica-
tions, but especially with DPN, compared with oral
hypoglycemic agents. The association continued to
remain quite strong after adjusting for multiple varia-
bles including diabetes duration, HbA1c, and sex (Sav-
age et al., 1997). In the San Luis Valley Diabetes
Table 1. Association of the presence of neuropathy and base-
line characteristics.
Characteristic N Neuropathy (%) p
Age (years)





Female 682 46.2 0.005
Male 1,632 52.6
Race/ethnicity
White non-Hispanic 1,518 50.9 0.026




,7 906 47.7 0.021
7 1,403 52.6
Diabetes duration (years)





,30 1,014 49.2 0.208
30 1,300 51.8
History of hypertension
No 401 42.6 ,0.001
Yes 1,885 52.1
Blood pressure (mmHg)*
130/80 1,097 50.1 0.569
.130/80 1,210 51.3
Urine albumin : creatinine ratio
30 1,450 48.1 ,0.001
.30 697 57.2
HDL (mg/dl)*
.40male/.50 female 558 47.8 0.112
40male/50 female 1,750 51.7
LDL (mg/dl)*
,100 1,346 51.3 0.498
100 928 49.9
Triglycerides (mg/dl)*
,150 1,165 50.3 0.704
150 1,147 51.1
Current cigarette use
No 2,028 51.1 0.287
Yes 285 47.7
Alcohol consumption
Not regular 1,696 51.9 0.101
Regular 376 46.0
Binge 242 49.2
HDL,high-density lipoprotein;LDL, low-density lipoprotein.
*Seventy-ninepercentofpatientswere takingat least one kindof lipid-lower-
ing agent at baseline; 96% of patients took at least one kind of antihyperten-
sive agent at baseline. Lipid-lowering agents include statins, fibrates, niacin,
bile acid sequestrants, omega-3 fatty acid, and cholesterol absorption inhibi-
tor. Antihypertensive agents include beta blockers, calcium channel block-


















Figure 1. Distribution of Michigan Neuropathy Screening
Instrument clinical score in the Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes cohort at baseline.
Scores with 0.5 increments were rounded up to the next
integer.
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Study of 277 T2DM subjects, insulin use was a strong
independent factor associated with DPN (Franklin
et al., 1994). In a European case-control cohort of
1,300 subjects with diabetes, treatment with insulin
was significantly associated with the presence of
lower limb complications in spite of similar prevalence
of other complications or comorbidities (el-Shazly
et al., 1998). The current study extends these prior
observations on diabetes and DPN to a much larger
and well-characterized population of more than 2,000
T2DM patients recruited through the BARI 2D trial.
The population is also well represented by black non-
Hispanics (17%) and Hispanics (13%).
As for the other epidemiologic studies, the cross-
sectional results presented here cannot address causal-
ity between insulin use and DPN. The reasons why a
certain glycemic control therapy was prescribed are not
known. The presence of DPN may have prompted the
initiation of insulin therapy to forestall worsening DPN
and other microvascular complications. If insulin therapy
was added after the failure of diet and various oral hypo-
glycemic agents singly or in combination then the insu-
lin-use cohort could have had several periods of poor
glycemic control before the therapy was intensified.
Also, the association of insulin use and DPN must be
taken in the context that moderately severe CAD was
a selection criterion for the BARI 2D cohort. The devel-
opment of DPN may be affected by the presence of
atherosclerosis and possible peripheral artery disease.
Besides methodological issues related to the
cross-sectional study design, insulin use could be
associated with DPN by nerve damage from exoge-
nous insulin. Some have previously postulated that
exogenous insulin therapy in T2DM might be associ-
ated with DPN through an exacerbation of obesity,
fluid retention, hypertension, and hyperlipidemia
(Savage et al., 1997). However, several randomized
clinical trials in T1DM have shown that intensive insu-
lin therapy can prevent or delay the development of
DPN compared with conventional insulin therapy
(DCCT Research Group, 1995; Ohkubo et al., 1995).
Additionally, experimental evidence suggests that,
beyond improving glycemic control, insulin may have
complex protective vascular actions (Pop-Busui and
Stevens, 2005).
Another possible explanation for the association
of insulin use with the prevalence of DPN in this
cohort could be that insulin use indicates beta-cell fail-
ure in a group of patients. If insulin therapy was initi-
ated because of beta-cell failure then it may be
a biologic marker of a later stage of the natural history
of diabetes and more accurately reflect the severity of
diabetes than the HbA1c levels or the reported dura-
tion of diabetes in patients for whom the true onset of
diabetes is not clear. In addition, several mechanisms
such as glucotoxicity per se and its downstream
increase in oxidative stress and free fatty acids have
been shown to negatively impact beta-cell function
and to induce peripheral nerve damage and thus could
have contributed to the association we found with
Table 2. Clinical characteristics andunadjusted odds ratio of diabetic peripheral neuropathy by glycemic control group.
Characteristics
Glycemic controlmedication
Met/TZD* No DMdrug SU Met/TZDþSU Insulin p
Number of patients 366 199 388 716 645 ^
Mean age (years) 61.2 62.6 63.7 62.4 62.2 0.004
Mean duration of DM (years) 5.3 3.7 8.2 10.9 16.3 ,0.001
Mean HbA1c (%) 7.1 6.7 7.4 7.7 8.3 ,0.001
%Having neuropathy 41.5 43.2 51.8 49.9 58.4 ,0.001
Unadjusted odds ratio (95% CI) Reference group 1.07 (0.76^1.52) 1.51` (1.14^2.02) 1.40` (1.09^1.81) 1.98` (1.53^2.57) ^
Met,metformin;TZD, thiazolidinediones;SU, sulfonylurea;DM,diabetesmellitus;HbA1c,hemoglobinA1c.
















No DM drug SU Met/TZD+SU Insulin
Reference Group: Met/TZD
Figure 2. Odds ratios for diabetic peripheral neuropathy by
glycemic control therapy. Reference group: metformin/
thiazolidinediones. The full model was adjusted for sex,
age, race/ethnicity, duration of diabetes diagnosis, body
mass index, hemoglobin A1c, high-density lipoprotein, low-
density lipoprotein, triglycerides, systolic blood pressure,
current cigarette use, and alcohol consumption.
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insulin use and DPN (Pop-Busui et al., 2006). The
decrease in C-peptide secretion that accompanies
beta-cell failure may also directly contribute to neuro-
pathy because evidence from animal models suggests
that C-peptide can reverse DPN (Stevens et al., 2004).
However, this still needs to be confirmed in humans.
Another interesting observation is the trend
toward DPN protection observed in the Met/TZD
group, which raises the question whether different
pharmacologic and molecular effects of various
antihyperglycemic treatments may also play a role. A
large prospective clinical trial has suggested that the
beneficial effect of Met on the incidence of diabetes
complications was not entirely related to its glycemic
effects (UKPDS Group, 1998a). For instance, Met has
pleiotropic effects with direct vascular implications,
such as improvements in lipid profiles (Wu et al.,
1990), prevention of oxidative stress-induced endo-
thelial cell death (Detaille et al., 2005), and direct
neuroprotective effects via inhibition of oxidative
stress-related apoptotic cell death in primary neurons
(El-Mir et al., 2008). On the other hand, SUs promote
increases in circulating insulin levels by closing beta-
cell ATP-dependent potassium channels (Kþ-ATP),
and Kþ-ATP channels are widely expressed on neu-
rons. Data from animal studies have shown that
blockage of the Kþ-ATP channels with SU may selec-
tively potentiate neuronal mitochondrial dysfunction
and neurotoxicity by potentiating mitochondrial in-
hibitors (Kou et al., 2006) and glutamate-induced
generation of superoxide (Yamauchi et al., 2003),
although similar human data are not yet reported. In
the United Kingdom Prospective Diabetes Study,
intensive blood glucose control by SU did not
decrease the risk of DPN, whereas it substantially
decreases the risk of retinopathy and nephropathy
(UKPDS Group, 1998b).
TZDs may provide additional beneficial vascular
effects beyond glycemic improvement, such as reduc-
tion of inflammation (Sjoholm and Nystrom, 2005),
oxidative stress (Chen et al., 2004), and improvement
in endothelial dysfunction (Sjoholm and Nystrom,
2005), all important mechanisms involved in the path-
ogenesis of DPN. In addition, preclinical evidence
indicates that TZDs may exert direct neuroprotective
effects after cerebral ischemia and motor neuron loss,
myelin, and microglial activation after spinal cord injury
by inhibition of nuclear factor-kappaB and c-Jun N-termi-
nal kinases activation and oxidative stress-mediated
neuronal damage (Xing et al., 2007; Rosa et al., 2008;
Yu et al., 2008).
In summary, the findings of this cross-sectional,
baseline study in a cohort of patients with T2DM and
confirmed CAD suggest that insulin use was associ-
ated with a higher prevalence of DPN and that the use
of Met/TZD had a trend toward protection, indepen-
dent of disease duration, glycemic control, and other
characteristics. A better understanding of the role of
diabetes medications and other factors in the develop-
ment of DPN are likely at the conclusion of the BARI
2D trial because the analysis will include standardized
annual DPN exams on a well-characterized population
who received aggressive medical therapy and insulin-
sensitizing or insulin-providing agents in a controlled
and randomized fashion for the 5 years of the trial.
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Appendix 1. Bypass Angioplasty
Revascularization Investigation 2
Diabetes (BARI 2D) Investigators
BARI 2D, coordinating center, University of
Pittsburgh, Pittsburgh, Pennsylvania
Principal investigator: Katherine M. Detre, MD, DrPH,
Sheryl F. Kelsey, PhD
Co-principal investigator: Maria Mori Brooks, PhD
Co-investigators: David Kelley, MD, Trevor J. Orchard,
MBBCh, MmedSci, Jamal Rana, MD, PhD, Stephen
B. Thomas, PhD, Kim Sutton Tyrrell, RN, DrPH,
Richard Holubkov, PhD
Coordinator: Frani Averbach, MPH, RD
Administrative coordinators: Sharon W. Crow, BS,
Joan M. MacGregor, MS, Scott M. O’Neal, MA,
Kathleen Pitluga, BA, Veronica Sansing, BA, Mary
Tranchine, BS
Statisticians: Regina Hardison, MS, Kevin Kip, PhD,
Jiang Lu, MS, Manuel Lombardero, MS
Data managers: Sue Janiszewski, MSIS, Darina Pro-
tivnak, MSIS, Sarah Reiser, BS
System programmers: Stephen Barton, ASB, Yulia
Kushner, BS, BA, Owen Michael, ASB
System support: Jeffrey P. Martin, MBA, Christopher
Kania, BS, Michael Kania, BS, Jeffrey O’Donnell, BS
Consultant: Rae Ann Maxwell, RPh, PhD
Office of Study Chair, Mayo Clinic Foundation,
Rochester, Minnesota
Robert L. Frye, MD, Professor of Medicine
Program Office, National Heart, Lung and Blood
Institute, Bethesda, Maryland, National Institutes
of Health, Bethesda, Maryland
Project officer: Suzanne Goldberg, RN, MSN
Deputy project officer: Yves Rosenberg, MD, MPH
NHLBI officers: Patrice Desvigne-Nickens, MD, Abby
Ershow, ScD, David Gordon, MD, PhD, Dina Paltoo,
PhD, MPH
Co-funded by National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes
of Health, Bethesda, Maryland
Program director for diabetes complications: Teresa
L. Z. Jones, MD
List of participants, clinical centers
University of Sao Paulo Heart Institute, São Paulo,
Brazil
Principal investigators: Whady Hueb, MD, Cardiology,
José Ramires, MD, Cardiology, Neuza Lopes, MD,
Cardiology, Bernardo Wajchenberg, MD, Diabetology
Investigators: Eulogio E Martinez, MD, Sergio A
Oliveira, MD
Coordinator: Roberto Betti, MD
Toronto General Hospital/University Health Net-
work, Toronto, Canada
Principal investigators: Leonard Schwartz, MD, Cardi-
ology, George Steiner, MD, Diabetology
Investigators: Alan Barolet, MD, Yolanda Groene-
woud, MD
Coordinators: Kathy Camelon, RD, CDE, Lisa Mighton,
RN, CDE
Texas Health Science at San Antonio/South Texas
Veterans Health Care System, San Antonio, Texas
Principal investigators: Robert O’Rourke, MD, Cardio-
logy, Janet Blodgett, MD, Diabetology
Investigators: Edward Sako, MD, PhD
Coordinators: Judith Nicastro, RN, Robin Prescott,
MSN
Mayo Clinic-Rochester (Vanguard Site), Rochester,
Minnesota
Principal investigators: Charanjit Rihal, MD, Cardio-
logy, Frank Kennedy, MD, Diabetology
Investigators: Gregory Barsness, MD, Amanda Basu,
MD, Alfredo Clavell, MD, Robert Frye, MD, David R.
Holmes Jr, MD, Amir Lerman, MD, Charles Mullaney,
MD, Guy Reeder, MD, Robert Rizza, MD, Hartzell
Schaff, MD, Steven Smith, MD, Virend Somers, MD,
Thoralf Sundt, MD, Henry Ting, MD, R Scott Wright,
MD
Coordinators: Pam Helgemoe, RN, Diane Lesmeister,
Deborah Rolbiecki, LPN
Mexican Institute of the Social Security, Mexico
City, Mexico
Principal investigators: Luis Lepe-Montoya, MD, Cardi-
ology, Jorge Escobedo, MD, FACP, Diabetology
Investigators: Rafael Barraza, MD, Rubén Baleón, MD,
Arturo Campos, MD, Paula Garcı́a, MD, Carlos Leza-
ma, MD, Carlos Miramontes, MD, Salvador Ocampo,
MD, Joaquı́n V. Peñafiel, MD, Arquı́mides Valdespino,
MD, Raúl Verdı́n, MD, Héctor Albarrán, MD, Fernando
Ayala, MD, Eduardo Chávez, MD, Héctor Murillo, MD
Coordinators: Luisa Virginia Buitrón, MD, Beatriz Rico-
Verdin, MD, PhD
University Hospitals of Cleveland/CASE Medical
School (Vanguard Site), Cleveland, Ohio
Principal investigators: Dale Adler, MD, Cardiology,
Austin Arthur Halle, MD, Cardiology, Faramarz Ismail-
Beigi, MD, PhD, Diabetology
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Investigators: Suvinay Paranjape, MD
Coordinators: Stacey Mazzurco, RN, Karen Ridley, RN,
BSN
Memphis VA Medical Center/University of Ten-
nessee, Memphis, Tennessee
Principal investigators: Kodangudi Ramanathan, MD,
Cardiology, Solomon Solomon, MD, Diabetology
Investigators: Darryl Weinman, MD, Cardiology, Barry
Wall, MD, Nephrology
Coordinators: Lillie Douglas, RN, Tammy Touchstone,
RN, BSN
Montréal Heart Institute/Hôtel-Dieu-CHUM (Van-
guard Site), Montréal, Canada
Principal investigators: Martial Bourassa, MD, Cardiol-
ogy, Jean-Claude Tardif, MD, Cardiology, Jean-Louis
Chiasson, MD, Diabetology, Marc Andre Lavoie, MD,
Diabetology
Coordinators: Hélène Langelier, BSC, RD, Suzy Fouch-
er, RN, BA, Johanne Trudel, RN, BSc
Albert Einstein College of Medicine/Montefiore,
Bronx, New York
Principal investigators: Scott Monrad, MD, Cardiology,
Vankeepuram Srinivas, MD, Cardiology, Joel Zons-
zein, MD, Diabetology
Investigators: Jill Crandall, MD
Coordinators: Helena Duffy, ANP, CDE, Eugen
Vartolomei, MD
Fuqua Heart Center/Piedmont Hospital, Atlanta,
Georgia
Principal investigators: Spencer King III, MD, Cardiol-
ogy, Carl Jacobs, MD, Cardiology, David Robertson,
MD, Diabetology
Coordinators: Jennifer LaCorte, RN, BSN, CCRN, Me-
linda Mock, RN, BSN, MA, Marty Porter, PhD
University of Alabama at Birmingham (Vanguard
Site), Birmingham, Alabama
Principal investigators: William Rogers, MD, Cardiol-
ogy, Fernando Ovalle, MD, Diabetology, David Bell,
MBBCh, Diabetology
Investigators: Vijay K Misra, MD, William B Hillegass,
MD, Raed Aqel, MD
Coordinators: Penny Pierce, RN, BSN, Melanie Smith,
RN, BSN, Leah Saag, RN, Ashley Vaughn, RN, Dwight
Smith, RN, Tiffany Grimes, RN, Susan Rolli, RN,
Roberta Hill, RN, Beth Dean Barrett, RN, Clarinda
Morehead, LPN, Ken Doss
Northwestern University Medical School, Chicago,
Illinois
Principal investigators: Charles J. Davidson, MD,
Cardiology, Mark Molitch, MD, Diabetology
Investigators: Nirat Beohar, MD
Coordinators: Lynne Goodreau, RN, Elaine Massaro,
MS, RN, CDE, Fabiola Arroyo, CCT
Na Homolce Hospital, Prague, Czech Republic
Principal investigators: Lenka Pavlickova, MD, Cardio-
logy, Petr Neužil, MD, PhD, Cardiology, Štèpánka
Stehlı́ková, MD, Diabetology
Investigators: Jaroslav Benedik, MD
Coordinators: Liz Coling
University of Ottawa Heart Institute/Ottawa
Hospital-Riverside Campus, Ottawa, Canada
Principal investigators: Richard Davies, MD, Cardiol-
ogy, Christopher Glover, MD, Cardiology, Michel
LeMay, MD, Cardiology, Thierry Mesana, MD, Cardiol-
ogy, Teik Chye Ooi, MD, Diabetology, Mark Silverman,
MD, Diabetology, Alexander Sorisky, MD, Diabetology
Coordinators: Colette Favreau, RN, Susan McClinton,
BScN
New York Medical College/Westchester Medical
Center, Valhalla, New York
Principal investigators: Melvin Weiss, MD, Cardiology,
Irene Weiss, MD, Diabetology
Investigators: Leo Saulle, MD, Harichandra Kannam,
MD
Coordinators: Joanne C. Kurylas, RN, CDE, Lorraine
Vasi, RN
Emory University, Atlanta, Georgia
Principal investigators: John Douglas Jr, MD, Cardiol-
ogy, Ziyad Ghazzal, MD, Cardiology, Laurence Sperl-
ing, MD, Cardiology, Spencer King III, MD, Cardiology,
Priya Dayamani, MD, Diabetology, Suzanne Gebhart,
MD, Diabetology
Investigators: Sabreena Basu, MD, Tarek Helmy, MD,
Vin Tangpricha, MD, PhD
Coordinators: Pamela Hyde, RN, Margaret Jenkins,
RN, CDE
Washington Hospital Center/Georgetown Univer-
sity Medical Center, Washington, DC
Principal investigators: Kenneth Kent, MD, Cardiology,
William Suddath, MD, Cardiology, Michelle Magee,
MD, Diabetology
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Coordinator: Patricia Julien-Williams, CNP, Vida Reed,
RN, CDE Carine Nassar, RD, MD, CDE
Quebec Heart Institute/Laval Hospital, Sainte-Foy,
Canada
Principal investigators: Gilles Dagenais, MD, Cardiol-
ogy, Claude Garceau, MD, Diabetology
Coordinator: Dominique Auger, RN
University of British Columbia/Vancouver Hospi-
tal, British Columbia, Canada
Principal investigators: Christopher Buller, MD, Cardi-
ology, Tom Elliott, MBBS, Diabetology
Investigators: Krishnan Ramanathan, MD
Coordinators: Rebecca Fox, PA, MSc, Daniella Ko-
lesniak, MD
NYU School of Medicine, New York, New York
Principal investigators: Michael Attubato, MD, Cardiol-
ogy, Frederick Feit, MD, Cardiology, Stephen Richard-
son, MD, Diabetology
Investigators: Ivan Pena-Singh, MD, James Slater, MD
Coordinator: Angela Amendola, PA, Bernardo Vargas,
BS, Susan Cotton Gray, NP, Dallas Regan, MSN, NP
Lahey Clinic Medical Center (Vanguard Site),
Burlington, Massachusetts
Principal investigators: Nicholas Tsapatsaris, MD, Car-
diology, Bartholomew Woods, MD, Cardiology, Gary
Cushing, MD, Diabetology
Investigators: Martin Rutter, MD, Premranjan Singh, MD
Coordinators: Gail DesRochers, RN, Gail Woodhead,
RN, Deborah Gannon, MS, Nancy Shinopulos Camp-
bell, RN
University of Virginia, Charlottesville, Virginia
Principal investigators: Michael Ragosta, MD, Cardiol-
ogy, Ian Sarembock, MD, Cardiology, Eugene Barrett,
MD, Diabetology
Investigators: Eric Powers, MD
Coordinators: Linda Jahn, RN, MEd, Karen Murie, RN
University of Minnesota/Minnesota Veterans
Research Institute, Minneapolis, Minnesota
Principal investigators: Gladwin Das, MB, BS, MD,
Cardiology, Gardar Sigurdsson, MD, Cardiology, Carl
White, MD, Cardiology, John Bantle, MD, Diabetology
Investigators: J. Bruce Redmon, MD
Coordinators: Christine Kwong, MPH, RD, CDE
St. Luke’s/Roosevelt Hospital Center, New York,
New York
Principal investigators: Jacqueline Tamis-Holland, MD,
Cardiology, Jeanine Albu, MD, Diabetology
Investigators: Judith S. Hochman, MD, James Slater,
MD, James Wilentz, MD
Coordinators: Sylvaine Frances, PA, Deborah Tormey,
RN
University of Florida, Gainesville, Florida
Principal investigators: Carl Pepine, MD, Cardiology,
Karen Smith, MD, Cardiology, Laurence Kennedy,
MD, Diabetology
Coordinators: Karen Brezner, CCRC, Tempa Curry, RN
Saint Louis University, St. Louis, Missouri
Principal investigators: Frank Bleyer, MD, Cardiology,
Stewart Albert, MD, Diabetology
Investigators: Arshag Mooradian, MD
Coordinator: Sharon Plummer, NP
University of Texas at Houston, Houston, Texas
Principal investigators: Francisco Fuentes, MD, Cardi-
ology, Roberto Robles, MD, Cardiology, Victor Lavis,
MD, Diabetology
Investigators: Jaime Gomez, MD
Coordinators: Carol Underwood, BSN, RN, CCRC,
Maria Selin Fulton, RN, CDE, Julie Gomez Ramirez,
BSN, RN, Jennifer Merta, MA, Glenna Scott, RN
Kaiser-Permanente Medical Center, San Jose,
California
Principal investigators: Ashok Krishnaswami, MD, Car-
diology, Lynn Dowdell, MD, Diabetology
Coordinator: Sarah Berkheimer, RN
Henry Ford Heart & Vascular Institute, Detroit,
Michigan
Principal investigators: Adam Greenbaum, MD, Cardi-
ology, Fred Whitehouse, MD, Diabetology
Coordinators: Raquel Pangilinan, BSN, RN, Kelly
Mann, RN, BSN, CDE
Boston Medical Center, Boston, Massachusetts
Principal investigators: Alice Jacobs, MD, Cardiology,
Elliot Sternthal, MD, Diabetology
Investigators: Susana Ebner, MD
Coordinator: Paula Beardsley, LPN
Fletcher Allen Health Care (Vanguard Site), Col-
chester, Vermont
Principal investigators: David Schneider, MD, Cardiol-
ogy, Richard Pratley, MD, Diabetology
Investigators: William Cefalu, MD, Joel Schnure, MD
Coordinators: Michaelanne Rowen, RN, CCRC, Linda
Tilton, MS, RD, DE
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Jim Moran Heart & Vascular Institute, Fort
Lauderdale, Florida
Principal investigators: Alan Niederman, MD, Cardiol-
ogy, Cristina Mata, MD, Diabetology
Coordinator: Terri Kellerman, RN
Baylor College of Medicine, Houston, Texas
Principal investigators: John Farmer, MD, Cardiology,
Alan Garber, MD, Diabetology
Investigators: Neal Kleiman, MD
Coordinators: Nancy Howard, RN, BSN, Debra Nich-
ols, RN, Madonna Pool, RN, MSN
Duke University, Durham, North Carolina
Principal investigators: Christopher Granger, MD, Car-
diology, Mark Feinglos, MD, Diabetology
Investigators: George Adams, MD, Jennifer Green,
MD
Coordinators: Bernadette Druken, RN, CCRP, Dani
Underwood, MSN, ANP
University of Maryland Hospital, Baltimore,
Maryland
Principal investigators: J. Lawrence Stafford, MD, Car-
diology, Thomas Donner, MD, Diabetology
Investigators: Warren Laskey, MD
Coordinators: Dana Beach, RN
University of Chicago Medical Center, Chicago,
Illinois
Principal investigators: John Lopez, MD, Cardiology,
Andrew Davis, MD, Diabetology
Investigators: David Faxon, MD, Sirimon Reutrakul, MD
Coordinator: Emily Bayer, RN, BSN
University of Pittsburgh Medical Center (Vanguard
Site), Pittsburgh, Pennsylvania
Principal investigators: Oscar Marroquin, MD, Cardiol-
ogy, Howard Cohen, MD, Cardiology, Mary Kor-
ytkowski, MD, Diabetology
Coordinators: Glory Koerbel, MSN, CDE, Lisa Bax-
endell, RN, Debbie Rosenfelder, BSN, CCRC, Louise
DeRiso, MSN, Carole Farrell, BSN, Tina Vita, RN
Washington University/Barnes Jewish Hospital,
St. Louis, Missouri
Principal investigators: Richard Bach, MD, Cardiology,
Ronald Krone, MD, Cardiology, Majesh Makan, MD,
Cardiology, Janet McGill, MD, Diabetology
Coordinators: Carol Recklein, RN, MHS, CDE, Kristin
M. Luepke, RN, MSN, Mary Jane Clifton
Mount Sinai Medical Center, New York, New York
Principal investigators: Michael Farkouh, MD, MSc,
Cardiology, Michael Kim, MD, FACC, Cardiology, Don-
ald A. Smith, MD, MPH, Diabetology
Coordinators: Ida Guzman, RN, BSN, ANP, MS, CDE,
Arlene Travis, RN
Mid America Heart Institute, Kansas City, Missouri
Principal investigators: James O’Keefe, MD, Cardiol-
ogy, Alan Forker, MD, Diabetology, William Isley, MD,
Diabetology
Investigators: Richard Moe, MD, PhD
Coordinators: Paul Kennedy, RN, Margaret Rosson,
LPN, Aimee Long, RN
University of Michigan, Ann Arbor, Michigan
Principal investigators: Eric Bates, MD, Cardiology,
William Herman, MD, MPH, Diabetology, Rodica Pop-
Busui, MD, Diabetology
Investigators: Claire Duvernoy, MD, Martin Stevens,
MBBCh
Coordinators: Ann Luciano, RN, Cheryl Majors, BSN
Johns Hopkins Bayview Medical Center, Baltimore,
Maryland
Principal investigators: Sheldon H. Gottlieb, MD, Car-
diology, Annabelle Rodriguez, MD, Diabetology
Coordinator: Melanie Herr, RN
Brown University/Rhode Island Hospital,
Providence, Rhode Island
Principal investigators: David Williams, MD, Cardio-
logy, Robert J. Smith, MD, Diabetology
Investigators: J. Dawn Abbott, MD, Marc J. Laufgraben,
MD
Coordinators: Mary Grogan, RN, Janice Muratori, RNP
Houston VA Medical Center, Houston, Texas
Principal investigators: Gabriel Habib, MD, MS, Cardi-
ology, Marco Marcelli, MD, Diabetology
Investigators: Issam Mikati, MD
Coordinators: Emilia Cordero, NP, Gina Caldwell, LVN
New York Hospital Queens, Queens, NY/Lang
Research Center
Principal investigators: David Schechter, MD, Cardiol-
ogy, Daniel Lorber, MD, Diabetology, Phyllis August,
MD, MPH, Nephrology
Coordinators: Maisie Brown, RN, MSN, Patricia
Depree, PhD, ANP, CDE
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Wilhelminen Hospital, Vienna, Austria
Principal investigators: Kurt Huber, MD, Cardiology,
Ursula Hanusch-Enserer, MD, Diabetology
Investigators: Nelly Jordanova, MD
Coordinators: Dilek Cilesiz, MD, Birgit Vogel, MD
St. Joseph Mercy Hospital/Michigan Heart and
Vascular Institute and the Ann Arbor Endocrinol-
ogy and Diabetes, P.C., Ann Arbor, Michigan
Principal investigators: Ben McCallister Jr, MD, Cardi-
ology, Kelly Mandagere, MD, Diabetology, Michael
Kleerekoper, MD, Diabetology, Robert Urbanic, MD,
Diabetology
Investigators: James Bengston, MD, MPH, Bobby K.
Kong, MD, Andrew Pruitt, MD, Jeffrey Sanfield, MD
Coordinators: Carol Carulli, RN, Ruth Churley-Strom,
MSN
The Ohio State University Medical Center, Colum-
bus, Ohio
Principal investigators: Raymond Magorien, MD, Car-
diology, Kwame Osei, MD, Diabetology
Coordinators: Cecilia Casey Boyer, RN
Mayo Clinic-Scottsdale, Scottsdale, Arizona
Principal investigators: Richard Lee, MD, Cardiology,
Pasquale Palumbo, MD, Diabetology
Coordinators: Susan Roston, RN, Joyce Wisbey, RN
Core laboratories
Angiographic Core Laboratory, Stanford Univer-
sity, Stanford, California
Principal investigator: Edwin Alderman, MD, Fumiaki
Ikeno, MD
Staff: Anne Schwarzkopf
Biochemistry Core Laboratory, University of Min-
nesota, Minneapolis, Minnesota
Principal investigator: Michael Steffes, MD, PhD
Staff: Maren Nowicki, CLS, Jean Bucksa, CLS
ECG Core Laboratory, Saint Louis University, St.
Louis, Missouri (U01 HL061746)
Principal investigator: Bernard Chaitman, MD
Staff: Jane Eckstein, RN, Teri Bertram, RN
Economics Core Laboratory, Stanford University,
Stanford, California (U01 HL061748)
Principal investigator: Mark A. Hlatky, MD
Staff: Derek B. Boothroyd, PhD, Kathryn A. Melsop, MS
Fibrinolysis Core Laboratory, University of Ver-
mont, Burlington, Vermont (U01 HL063804)
Principal investigator: Burton E. Sobel, MD
Staff: Michaelanne Rowen, RN, CCRC, Dagnija Nei-
mane, BS
Nuclear Cardiology Core Laboratory, University of
Alabama at Birmingham, Birmingham, Alabama
(Astellas Pharma US, Inc.)
Principal investigators: Ami E. Iskandrian, MD
Staff: Mary Beth Schaaf, RN, BSN
Management centers
Diabetes Management Center, Case Western
Reserve University, Cleveland, Ohio
Director: Saul Genuth, MD
Staff: Theresa Bongarno, BS
Hypertension Management Center, Lahey Clinic
Medical Center, Burlington, Massachusetts
Co-director: Richard Nesto, MD
Hypertension Management Center, New York
Hospital Queens, Queens, New York
Co-director: Phyllis August, MD
Staff: Karen Hultberg, MS
Lifestyle Intervention Management Center, Johns
Hopkins Bayview Medical Center, Baltimore,
Maryland
Co-director: Sheldon H. Gottlieb, MD
Lifestyle Intervention Management Center, St.
Luke’s/Roosevelt Hospital Center, New York,
New York
Co-director: Jeanine Albu, MD
Staff: Helene Rosenhouse-Romeo, RD, CDE
Lipid Management Center, University of Pitts-
burgh, Pittsburgh, Pennsylvania
Director: Trevor J. Orchard, MBBCh, MMedSci
Staff: Georgia Pambianco, MPH, Manuel Lombardero,
MS
Safety officer
Michael Mock, MD, North Canton, Ohio
Operations committee
Chair: Robert L. Frye, MD
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Members: Maria Mori Brooks, PhD, Patrice Desvigne-
Nickens, MD, Abby Ershow, ScD, Saul Genuth, MD,
Suzanne Goldberg, RN, MSN, David Gordon, MD, PhD,
Regina Hardison, MS, Teresa L. Z. Jones, MD, Sheryl
Kelsey, PhD, Richard Nesto, MD, Trevor Orchard,
MBBCh, MMedSci, Dina Paltoo, PhD, MPH, Yves
Rosenberg, MD, MPH
Morbidity and Mortality Classification Committee
Chair: Thomas Ryan, MD
Co-chair: Harold Lebovitz, MD
Members: Robert Brown, MD, Gottlieb Friesinger,
MD, Edward Horton, MD, Jay Mason, MD, Renu
Virmani, MD, Lawrence Wechsler, MD
Data and Safety Monitoring Board
Chair: C. Noel Bairey-Merz, MD, J. Ward Kennedy,
MD (former)
Executive secretary: David Gordon, MD, PhD
Members: Elliott Antman, MD, John Colwell, MD,
PhD, Sarah Fowler, PhD, Curt Furberg, MD, Lee Gold-
man, MD, Bruce Jennings, MA, Scott Rankin, MD
Deceased.
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